Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, includ…
Biotechnology
US, Plano [HQ]
Balance Sheet
10 Sheets · Starting from 2022In Million USD. Margins, Growth Rates In %
| Metric | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | 229.00 | 125.00 | 78.00 | 89.00 | 135.00 | 345.00 | 682.00 | 857.00 | 735.00 | 514.00 | |
|
Current
|
192.00 | 106.00 | 77.00 | 87.00 | 133.00 | 342.00 | 669.00 | 847.00 | 596.00 | 397.00 | |
| Cash And Equivalents | 176.00 | 87.00 | 42.00 | 84.00 | 129.00 | 337.00 | 664.00 | 818.00 | 590.00 | 42.00 | |
| Assets | 229.00 | 125.00 | 78.00 | 89.00 | 135.00 | 345.00 | 682.00 | 857.00 | 735.00 | 514.00 | |
| Accounts Receivables (AR) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Inventory | - - | - - | - - | - - | - - | - - | - - | -22.00 | - - | - - | |
| Short Term Investments | - - | - - | - - | - - | - - | - - | - - | - - | - - | 345.00 | |
| Other Current Assets | - - | - - | - - | - - | - - | 4.00 | 4.00 | 29.00 | 6.00 | 10.00 | |
|
Non Current
|
37.00 | 18.00 | 1.00 | 1.00 | 2.00 | 2.00 | 13.00 | 10.00 | 138.00 | 116.00 | |
| Property, Plant, Equipment (Net) | 4.00 | 2.00 | 1.00 | - - | - - | 1.00 | 2.00 | 4.00 | 138.00 | 116.00 | |
|
Intangible Assets
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Goodwill | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Long Term Investments | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Non Current Assets | - - | - - | - - | - - | 1.00 | 1.00 | 10.00 | 5.00 | - - | - - | |
| Liabilities | 506.00 | 399.00 | 352.00 | 304.00 | 282.00 | 330.00 | 425.00 | 440.00 | 549.00 | 580.00 | |
|
Current
|
115.00 | 58.00 | 60.00 | 59.00 | 47.00 | 55.00 | 192.00 | 119.00 | 53.00 | 58.00 | |
| Accounts Payable | - - | -1.00 | 2.00 | - - | -1.00 | 1.00 | -2.00 | 2.00 | 8.00 | 5.00 | |
| Short Term Debt | 58.00 | 4.00 | 3.00 | 6.00 | 1.00 | 15.00 | 173.00 | 87.00 | 3.00 | 2.00 | |
| Deferred Revenue | 51.00 | 49.00 | 49.00 | 46.00 | 28.00 | 31.00 | 4.00 | 4.00 | 1.00 | - - | |
| Tax Payable | 58.00 | 1.00 | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Current Liabilities | 61.00 | 7.00 | 7.00 | 9.00 | 16.00 | 4.00 | 11.00 | 22.00 | 35.00 | 38.00 | |
|
Non Current
|
391.00 | 341.00 | 291.00 | 244.00 | 234.00 | 274.00 | 233.00 | 320.00 | 495.00 | 521.00 | |
| Long Term Debt | - - | - - | - - | - - | 18.00 | 79.00 | 155.00 | - - | 136.00 | 117.00 | |
| Leasing Obligations | - - | - - | - - | - - | - - | - - | - - | - - | 136.00 | 119.00 | |
| Deferred Non Current Tax Liabilities | - - | - - | - - | - - | -28.00 | -31.00 | 62.00 | - - | - - | - - | |
| Other Non Current Liabilities | 1.00 | - - | - - | -46.00 | -28.00 | - - | 6.00 | 316.00 | 359.00 | 403.00 | |
| Equity | -277.00 | -274.00 | -273.00 | -289.00 | -337.00 | -420.00 | -710.00 | -958.00 | -1,255.00 | -65.00 | |
| Stockholders' Equity | -277.00 | -274.00 | -273.00 | -289.00 | -337.00 | -420.00 | -710.00 | -958.00 | -1,255.00 | -65.00 | |
| Retained Earnings | -282.00 | -281.00 | -283.00 | -289.00 | -337.00 | -420.00 | -710.00 | -958.00 | -1,255.00 | -1,567.00 | |
| Common Stock | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Preferred Stock | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Profit | -35.00 | - - | -1.00 | -6.00 | -47.00 | -80.00 | -290.00 | -247.00 | -297.00 | -311.00 | |
| Dividends | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Minority Interest | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Stockholders' Equity | 5.00 | 7.00 | 9.00 | - - | - - | 12.00 | - - | - - | - - | 1,501.00 | |
| Loss Other Compr. Income | - - | - - | - - | - - | - - | -12.00 | - - | - - | - - | - - |